Rep. Julie Johnson Purchases Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Representative Julie Johnson (D-Texas) recently bought shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on February 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on January 15th. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Dell Technologies (NYSE:DELL) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of ALLETE (NYSE:ALE) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 1/27/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 1/17/2025.

Regeneron Pharmaceuticals Stock Up 0.3 %

Regeneron Pharmaceuticals stock traded up $2.24 during mid-day trading on Friday, hitting $676.51. The company’s stock had a trading volume of 162,673 shares, compared to its average volume of 936,775. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The company has a market cap of $74.34 billion, a PE ratio of 17.65, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. The firm’s 50 day moving average is $709.01 and its 200 day moving average is $900.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.86 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter worth $26,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Avalon Trust Co acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Finally, Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $36,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on REGN. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Truist Financial cut their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Citigroup lowered their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. JPMorgan Chase & Co. cut their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Finally, Evercore ISI decreased their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $973.13.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.